News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Novocure to Report Third Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting
Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Xencor to Present Multiple Posters at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three
Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa
Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The platform has the capability to reduce
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Announces Opening of RightSourceSM Laboratory, Supporting Stevenage Biocluster
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the opening of another RightSourceSM facility, and first in the United Kingdom, which will provide services to the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
PINC AI™ and Fortune Name the Nation’s 100 Top Hospitals®
PINC AI™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 100 top hospitals. The full list of recognized hospitals was published in an exclusive
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December
ICON plc Schedules Third Quarter 2023 Earnings Conference Call
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2023 after the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
LivaNova to Announce Third-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time
Charles River Laboratories to Host Virtual Investor Day
Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will host a virtual Meeting with Management on Thursday, September 21st, beginning at 8:30 a.m. ET.
This virtual
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc